They’ve got $5m cash and spending $600k per quarter and increasing. I’d say they are funded for 12 months to be conservative.
It all comes down to R&D delays, and we know that companies in the medical space always have hiccups and delays along the way.
This stock is a buy and forget for 2-3 years. At the current valuation there’s a chance of serious multibagging if positive results.
